Related Experiment Video

Updated: Jun 25, 2026

Metabolic Labeling of Leucine Rich Repeat Kinases 1 and 2 with Radioactive Phosphate
11:31

Metabolic Labeling of Leucine Rich Repeat Kinases 1 and 2 with Radioactive Phosphate

Published on: September 18, 2013

CHIP regulates leucine-rich repeat kinase-2 ubiquitination, degradation, and toxicity

Han Seok Ko1, Rachel Bailey, Wanli W Smith

  • 1Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.

Proceedings of the National Academy of Sciences of the United States of America
|February 7, 2009
PubMed

Insights

Carboxyl terminus of HSP70-interacting protein (CHIP) targets leucine-rich repeat kinase-2 (LRRK2) for degradation, offering a potential treatment for Parkinson's disease. Inhibiting HSP90 also degrades LRRK2, reducing its toxicity.

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Genetics

Background:

  • Leucine-rich repeat kinase-2 (LRRK2) mutations are a primary genetic cause of late-onset Parkinson's disease (PD).
  • Mutant LRRK2 may exert toxicity through a gain-of-function mechanism, necessitating strategies to control its expression and cytotoxicity.

Purpose of the Study:

  • To investigate the role of carboxyl terminus of HSP70-interacting protein (CHIP) in the regulation of LRRK2.
  • To explore the potential of modulating CHIP activity and HSP90 chaperone function as therapeutic strategies for LRRK2-associated Parkinson's disease.

Main Methods:

  • Investigated the interaction between CHIP and LRRK2 using binding and ubiquitination assays.
  • Examined the effect of CHIP overexpression and knockdown on LRRK2-mediated toxicity.
  • Assessed the impact of HSP90 inhibition on LRRK2 stability and cellular viability.

Main Results:

  • CHIP directly binds, ubiquitinates, and promotes the proteasomal degradation of LRRK2.
  • Overexpression of CHIP confers protection against mutant LRRK2 toxicity, while CHIP knockdown exacerbates it.
  • HSP90 forms a complex with LRRK2, and its inhibition by 17AAG leads to LRRK2 degradation and increased cell viability.

Conclusions:

  • Increasing CHIP E3 ligase activity can enhance LRRK2 degradation.
  • Blocking HSP90 chaperone activity provides a neuroprotective effect by reducing LRRK2 levels.
  • Targeting CHIP and HSP90 pathways represents a promising therapeutic avenue for LRRK2-related Parkinson's disease.

More Related Videos

In Vitro Analysis of E3 Ubiquitin Ligase Function06:06

In Vitro Analysis of E3 Ubiquitin Ligase Function

Published on: May 14, 2021

Assaying the Kinase Activity of LRRK2 in vitro06:09

Assaying the Kinase Activity of LRRK2 in vitro

Published on: January 18, 2012

Related Concept Videos

Regulated Protein Degradation02:58

Regulated Protein Degradation

It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Regulated Protein Degradation02:58

Regulated Protein Degradation

It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Covalently Linked Protein Regulators02:04

Covalently Linked Protein Regulators

Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein.
The Proteasome01:13

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...
The Proteasome02:18

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...